Publications by authors named "H G Genieser"

Protein kinase A (PKA), the main effector of cAMP in eukaryotes, is a paradigm for the mechanisms of ligand-dependent and allosteric regulation in signalling. Here we report the orthologous but cAMP-independent PKA of the protozoan Trypanosoma and identify 7-deaza-nucleosides as potent activators (EC ≥ 6.5 nM) and high affinity ligands (K ≥ 8 nM).

View Article and Find Full Text PDF
Article Synopsis
  • Inherited retinal degeneration (RD) is a severe and currently untreatable condition that causes loss of photoreceptor cells, leading to blindness, with challenges like genetic diversity and blood-retinal barrier hindering effective therapies.
  • The study focuses on targeting cGMP signaling, which plays a role in various RD types, and combines it with a nanosized liposomal drug delivery system to improve transport across the blood-retinal barrier.
  • Researchers identified an effective inhibitory cGMP analog that prevents photoreceptor cell death and, when encapsulated in liposomes, successfully preserved retinal function and reduced degeneration in multiple RD models.
View Article and Find Full Text PDF

Melanoma is one of the most aggressive cancers and displays high resistance to conventional chemotherapy underlining the need for new therapeutic strategies. The cGMP/PKG signaling pathway was detected in melanoma cells and shown to reduce migration, proliferation and to increase apoptosis in different cancer types. In this study, we evaluated the effects on cell viability, cell death, proliferation and migration of novel dimeric cGMP analogues in two melanoma cell lines (MNT1 and SkMel28).

View Article and Find Full Text PDF

Activation of the cGMP-dependent protein kinase G (PKG) can inhibit growth and/or induce apoptosis in colon cancer. In this study we evaluated the effects on cell viability, cell death and proliferation of novel dimeric cGMP analogues, compared to a monomeric compound. Three colon cancer cell lines, which only express isoform 2 of PKG, were treated with these novel cGMP analogues and responded with increased PKG activity.

View Article and Find Full Text PDF

After decades of intensive research on adenosine-3',5'-cyclic monophosphate (cAMP)- and guanosine-3',5'-cyclic monophosphate (cGMP)-related second messenger systems, also the noncanonical congeners cyclic cytidine-3',5'-monophosphate (cCMP) and cyclic uridine-3',5'-monophosphate (cUMP) gained more and more interest. Until the late 1980s, only a small number of cCMP and cUMP analogs with sometimes undefined purities had been described. Moreover, most of these compounds had been rather synthesized as precursors of antitumor and antiviral nucleoside-5'-monophosphates and hence had not been tested for any second messenger activity.

View Article and Find Full Text PDF